GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ACON · Jun 30, 2026

Aclarion, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 4[email protected]
Inspectable configuration

State dimensions

Filing0001683168-26-006026General Corporate
Operating cash generation29thOwn-history percentile · N=17
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-10540.51% · OPTIONAL · VALID

Revenue growth57thOwn-history percentile · N=14
Evidence method

Yoy · gp.fundamentals.revenue

30.48% · CORE · VALID

Gross margin100thOwn-history percentile · N=17
Evidence method

Level · gp.fundamentals.gross_margin

32.91% · CORE · VALID

Operating margin24thOwn-history percentile · N=17
Evidence method

Level · gp.fundamentals.operating_margin

-11503.18% · CORE · VALID

R&D intensity24thOwn-history percentile · N=17
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

1178.48% · OPTIONAL · VALID

SBC intensity41thOwn-history percentile · N=17
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

405.10% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History19 statesSelf-history eligible
Mar 31, 20220/5 normalizedLevel 3Jun 30, 20220/5 normalizedLevel 3Sep 30, 20220/5 normalizedLevel 3Dec 31, 20220/5 normalizedLevel 3Dec 31, 20220/6 normalizedAmended as filedMar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/6 normalizedLevel 3Dec 31, 20230/6 normalizedLevel 3Mar 31, 20245/6 normalizedLevel 3Jun 30, 20245/6 normalizedLevel 3Sep 30, 20245/6 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/6 normalizedLevel 3Jun 30, 20256/6 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20256/7 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 4
Period transition

What moved in the state?

Cash Generation Increased
Previous
-12496.90%
Current
-10540.51%
Delta
1956.39%
Growth Increased
Previous
11.32%
Current
30.48%
Delta
19.17%
Margin Increased
Previous
17.74%
Current
32.91%
Delta
15.18%
Profitability Increased
Previous
-14129.33%
Current
-11503.18%
Delta
2626.15%
R And D Intensity Decreased
Previous
1492.04%
Current
1178.48%
Delta
-313.56%
Sbc Intensity Increased
Previous
22.20%
Current
405.10%
Delta
382.89%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Dec 31, 2025
Similarity
81%
Compared
6 dimensions
Coverage
100%
Growth 17.9 · Margin 20.0 · Profitability 9.8 · Sbc Intensity 34.5 · Cash Generation 10.6 · R And D Intensity 9.8
Jun 30, 2025
Similarity
78%
Compared
6 dimensions
Coverage
100%
Growth 22.9 · Margin 7.7 · Profitability 22.6 · Sbc Intensity 41.2 · Cash Generation 1.4 · R And D Intensity 14.9
Sep 30, 2024
Similarity
66%
Compared
5 dimensions
Coverage
83%
Margin 70.0 · Profitability 16.5 · Sbc Intensity 21.2 · Cash Generation 10.6 · R And D Intensity 6.5
Mar 31, 2024
Similarity
45%
Compared
5 dimensions
Coverage
83%
Margin 100.0 · Profitability 11.0 · Sbc Intensity 21.3 · Cash Generation 16.9 · R And D Intensity 64.0
Research Graph

Related governed research

Analogous To · ACON state analogue 1 →Compared To · Services-Medical Laboratories peers →Analogous To · ACON state analogue 2 →Analogous To · ACON state analogue 3 →Analogous To · ACON state analogue 4 →Transitioned To · ACON Fundamental State →Transitioned To · ACON CASH_GENERATION_INCREASED →Transitioned To · ACON GROWTH_INCREASED →Transitioned To · ACON MARGIN_INCREASED →Transitioned To · ACON PROFITABILITY_INCREASED →Transitioned To · ACON R_AND_D_INTENSITY_DECREASED →Transitioned To · ACON SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.